SG10201707618TA - Cyclodextrin and antibody-drug conjugate formulations - Google Patents

Cyclodextrin and antibody-drug conjugate formulations

Info

Publication number
SG10201707618TA
SG10201707618TA SG10201707618TA SG10201707618TA SG10201707618TA SG 10201707618T A SG10201707618T A SG 10201707618TA SG 10201707618T A SG10201707618T A SG 10201707618TA SG 10201707618T A SG10201707618T A SG 10201707618TA SG 10201707618T A SG10201707618T A SG 10201707618TA
Authority
SG
Singapore
Prior art keywords
cyclodextrin
antibody
drug conjugate
conjugate formulations
formulations
Prior art date
Application number
SG10201707618TA
Other languages
English (en)
Inventor
Hui Li
Shan Jiang
Mary Wallace
Damon Meyer
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG10201707618TA publication Critical patent/SG10201707618TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201707618TA 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations SG10201707618TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780185P 2013-03-13 2013-03-13
US201361782231P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201707618TA true SG10201707618TA (en) 2017-10-30

Family

ID=51659070

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201707618TA SG10201707618TA (en) 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations
SG10202009046SA SG10202009046SA (en) 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations
SG11201506372RA SG11201506372RA (en) 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202009046SA SG10202009046SA (en) 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations
SG11201506372RA SG11201506372RA (en) 2013-03-13 2014-03-12 Cyclodextrin and antibody-drug conjugate formulations

Country Status (13)

Country Link
US (3) US9610361B2 (fr)
EP (1) EP2970444A4 (fr)
JP (2) JP6463725B2 (fr)
KR (3) KR102401525B1 (fr)
CN (1) CN105189546B (fr)
AU (2) AU2014248640B2 (fr)
CA (1) CA2901575C (fr)
EA (1) EA201591710A1 (fr)
HK (1) HK1220698A1 (fr)
IL (3) IL240598B (fr)
MX (2) MX2015011367A (fr)
SG (3) SG10201707618TA (fr)
WO (1) WO2014165119A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
EP3463463A4 (fr) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combinaison de conjugués anticorps cd33 médicament avec des agents chimiothérapeutiques
EP3469001A4 (fr) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
CN108452319A (zh) * 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物制剂
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
IL270415B1 (en) 2017-05-12 2024-04-01 Crispr Therapeutics Ag Materials and methods for cell engineering and their uses in immuno-oncology
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
BR112020004126A2 (pt) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited conjugado anticorpo-derivado de pirrolbenzodiazepina
EP3790899A1 (fr) 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procédés d'utilisation
EP3790629A1 (fr) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Procédés et compositions pour le traitement du cancer
EP3927729A4 (fr) 2019-02-18 2023-10-11 Eli Lilly and Company Formulation d'anticorps thérapeutique
JPWO2020196474A1 (fr) * 2019-03-25 2020-10-01
JPWO2020196712A1 (fr) * 2019-03-27 2020-10-01
WO2020222176A1 (fr) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
WO2022268050A1 (fr) * 2021-06-22 2022-12-29 荣昌生物制药(烟台)股份有限公司 Combinaison pharmaceutique et son utilisation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
PT88490B (pt) 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DE68906942T3 (de) 1988-03-29 1999-05-12 Univ Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
DE60132094T3 (de) 2001-10-26 2012-02-02 Octoplus Polyactive Sciences B.V. Verfahren zur Herstellung von gereinigten Partikeln
DE10361599A1 (de) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
WO2005065709A2 (fr) 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Formulation lyophilisee de conjugues d'anticorps
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
EP2358395A4 (fr) 2008-11-17 2013-11-20 Hoffmann La Roche Procédé et formulation pour réduire l'agrégation d'une macromolécule dans des conditions physiologiques
BRPI1008749B8 (pt) * 2009-02-05 2021-05-25 Immunogen Inc compostos derivados de benzodiazepina, seus conjugados, composição farmacêutica, seu uso e seus processos de preparação
US20110207764A1 (en) 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
EP2789622B1 (fr) 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines utilisés pour traiter des maladies proliférantes
KR101671360B1 (ko) 2010-04-15 2016-11-01 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
WO2012037643A1 (fr) * 2010-09-13 2012-03-29 Blinq Wireless Inc. Système et procédé de mesure de brouillage dans le même canal et d'attribution de ressources adaptative gérée pour la liaison de raccordement sans fil
EP3666289A1 (fr) 2011-02-15 2020-06-17 ImmunoGen, Inc. Dérivés de benzodiazépine cytotoxique
US20120321603A1 (en) 2011-06-16 2012-12-20 Nayan Patel Composition and method for stabilization and delivery of therapeutic molecules
EP2751111B1 (fr) 2011-10-14 2017-04-26 MedImmune Limited Dérivés asymmetriques de bis-(5H-pyrrolo[2,1-c][1,4]benzodiazépin-5-one) pour le traitement de maladies prolifératives ou auto-immunes
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EP3309162A1 (fr) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Conjugues cibles des pyrrolobenzodiazepines
HUE042373T2 (hu) * 2013-03-13 2019-06-28 Seattle Genetics Inc Aktív szenes szûrés benzodiazepin ADC-k tisztítására

Also Published As

Publication number Publication date
KR102274714B1 (ko) 2021-07-09
AU2014248640A1 (en) 2015-08-27
IL273359A (en) 2020-05-31
IL240598B (en) 2020-04-30
JP2019019140A (ja) 2019-02-07
US20160045615A1 (en) 2016-02-18
AU2018201985A1 (en) 2018-04-12
CN105189546B (zh) 2022-09-02
KR102401525B1 (ko) 2022-05-24
NZ751431A (en) 2020-11-27
AU2014248640B2 (en) 2018-03-01
WO2014165119A1 (fr) 2014-10-09
HK1220698A1 (zh) 2017-05-12
JP6463725B2 (ja) 2019-02-06
US9987374B2 (en) 2018-06-05
EA201591710A1 (ru) 2016-03-31
NZ711020A (en) 2020-11-27
AU2018201985B2 (en) 2019-07-18
IL273359B (en) 2021-12-01
CN105189546A (zh) 2015-12-23
CA2901575A1 (fr) 2014-10-09
KR20210087560A (ko) 2021-07-12
IL240598A0 (en) 2015-09-24
SG10202009046SA (en) 2020-10-29
US10391181B2 (en) 2019-08-27
CA2901575C (fr) 2022-08-30
JP2016512540A (ja) 2016-04-28
EP2970444A1 (fr) 2016-01-20
KR20150129697A (ko) 2015-11-20
MX2015011367A (es) 2015-12-16
MX2021005426A (es) 2021-06-15
KR20210024245A (ko) 2021-03-04
IL287559A (en) 2021-12-01
US9610361B2 (en) 2017-04-04
EP2970444A4 (fr) 2016-11-09
US20170232112A1 (en) 2017-08-17
US20180369408A1 (en) 2018-12-27
SG11201506372RA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
IL287559A (en) Formulations of antibody-drug conjugate and cyclodextrin
HRP20190056T1 (hr) Konjugat anti-trop2 antitijelo-lijek
HK1225319A1 (zh) 擬肽化合物及其抗體藥物偶聯物
IL246277A0 (en) Peptide-mimicking compounds and their antibody-drug conjugates
EP3049443A4 (fr) Conjugués anticorps anti-trop-2-médicament et leurs utilisations
HK1219422A1 (zh) 包含細胞結合劑及細胞毒素劑的軛合物
IL238567A0 (en) Antibodies against notch3 and antibody-drug conjugates
SI2958944T1 (sl) Konjugati protiDLL3-protitelo-PBD in njihove uporabe
HUE049291T2 (hu) Antitest-hatóanyag konjugátumok és immuntoxinok
PL3102606T3 (pl) Koniugaty przeciwciało-lek i immunotoksyny
EP3015116A4 (fr) Conjugué anticorps-médicament présentant une stabilité améliorée et son utilisation
HK1219423A1 (zh) 包含細胞結合劑及細胞毒素劑的軛合物
IL248925A0 (en) Curcumin-peptide conjugates and their formulations
IL245437A0 (en) Antibodies against efna4 and antibody-drug pairs
EP2968599A4 (fr) Conjugués ligand-agent thérapeutiques et lieurs à base de silicium
GB201310472D0 (en) Antibody-drug conjugates